Related by context. All words. (Click for frequent words.) 78 Initiates Clinical Trial 77 Antiangiogenic 77 Novel Therapeutic 76 Anti Tumor 76 Prolongs Survival 76 Epidermal Growth Factor Receptor 75 Therapeutic Vaccine 75 Successfully Completes Phase 75 Systemic Delivery 75 Kinase Inhibitor 75 oncolytic virus therapies 75 Aurora Kinase 75 Phase 2b Clinical Trial 75 Shows Promise Against 75 Completes Patient Enrollment 74 Cytotoxic 74 Oral Mucositis 74 Initiates Clinical 74 Initiate Clinical Trial 74 kidney urologic 74 Tyrosine Kinase Inhibitor 74 Combination REOLYSIN R 74 Phase 2b Trial 74 IL# PE#QQR 74 Receives Orphan Drug Designation 74 See CLINICAL PHARMACOLOGY 74 Factor Receptor 74 Meets Primary Endpoint 74 Vaccine Protects Against 74 FOLOTYN ® 74 Novel Vaccine 74 CYT# potent vascular disrupting 74 Initiates Enrollment 74 Renal Cancer 74 Immunomodulatory 74 Personalized Immunotherapy 74 Metastatic Melanoma 74 RNAi Therapeutic 73 Small Molecule 73 Novel Oral 73 Transdermal Delivery 73 Adjuvant Treatment 73 Schizophrenia Treatment 73 Therapeutic Antibody 73 Initiates Phase III 73 RNAi Therapeutics 73 HDAC Inhibitor 73 Anthracycline 73 candidates Azedra TM 73 Begins Dosing 73 Recombinant Human 73 Reports Preclinical Data 73 Hsp# Inhibitor 73 Antitumor 73 Leukemias 73 Protein Expression 73 Licenses Novel 73 Clinical Trial Results 73 Aflibercept 73 GVAX ® 73 Vaccine Adjuvant 73 Therapeutic Vaccines 73 Thiovir 73 Cancer Vaccines 73 Prostate Cancer Vaccine 72 targeted radiotherapeutic 72 Investigational Treatment 72 Hepatocellular Carcinoma 72 Achieves Primary Endpoint 72 Atopic Dermatitis 72 Cardiotoxicity 72 MEK Inhibitor 72 Presents Preclinical Data 72 essential thrombocythemia ET 72 Kinase Inhibitors 72 Drug Candidate 72 Phase 2a Clinical Trial 72 SinuNase ™ 72 Preclinical Models 72 R Saizen R 72 oral prodrug 72 Submits NDA 72 Genotyping Test 72 Phase IIb Trial 72 LymphoStat B TM 72 Fabry Disease 72 Advanced Melanoma 72 Develop Novel 72 Initiates Phase II 72 Files IND 72 Inflammatory Diseases 72 Severe Sepsis 72 Transdermal Patch 72 Romidepsin 72 platform HDL Mimetic 72 Solazed TM 72 Demonstrates Significant 72 Patients Treated With 72 Tumor Targeting 72 ALN HPN 72 Phase #b/#a clinical 72 HuMax 72 Entry Inhibitor 72 ARRY # 72 Lymphoid 72 Monoclonal Antibody 72 myelofibrosis polycythemia vera 72 Phase III Clinical Trial 72 thalidomide Thalomid 72 IND Application 72 tiuxetan 72 Novel Therapies 72 Chemotherapeutic 72 Factor VIIa 72 Allogeneic 72 mertansine 72 Adjuvanted 72 Oncolytic 72 Oral Fingolimod 72 Prodarsan R 72 JAK2 Inhibitor 72 SPRYCEL ® 71 Onalta TM 71 Interferon Beta 71 Demonstrates Positive 71 Signaling Pathway 71 Demonstrates Efficacy 71 Lymphocytic 71 Clinical Outcome 71 Monoclonal 71 Evoltra ® 71 Zorbtive TM 71 dasatinib Sprycel 71 Demonstrates Sustained 71 Mycophenolate Mofetil 71 IV Busulfex 71 metastatic malignant 71 Receives Orphan Drug 71 Mimetics 71 Protease Inhibitor 71 IND Filing 71 pralatrexate injection folate analogue 71 receptor tyrosine kinase inhibitor 71 R lenalidomide 71 Phase 2a Trial 71 Presents Positive 71 Antibody Discovery 71 Novel Small Molecule 71 Synthetic Peptide 71 Diabetic Neuropathy 71 novel VDA molecule 71 Shows Promising 71 FDA Okays 71 Drug Shows Promise 71 Cutaneous T 71 humanized monoclonal 71 Antigen Specific 71 Anti Angiogenic 71 Anti Angiogenesis 71 Neulasta ® 71 Granulocyte Colony Stimulating Factor 71 Present Preclinical Data 71 Respiratory Virus 71 XL# XL# 71 Squalamine 71 Gastric Cancer 71 Respiratory Syncytial Virus RSV 71 Prospective Randomized 71 Immunotherapies 71 TLK# 71 Cetrorelix 71 Allovectin 7 71 anti infective treatments 71 Rheumatoid Arthritis Drug 71 Demonstrates Potent 71 Nanoemulsion 71 Patient Enrollment 71 Azacitidine 71 erlotinib Tarceva ® 71 antibody MAb 71 evaluating tivozanib 71 Initiates Clinical Trials 71 Expanded Indication 71 Metabolic Disease 71 chimeric monoclonal antibody 71 Single Dose 71 Phase IIa Clinical Trial 71 Bosutinib 71 Angiotensin Converting Enzyme 71 Immunotherapeutics 71 NDA Submission 71 Glufosfamide 71 Antitumor Activity 71 rxRNA 71 Mg Usa 71 Transfection 71 histone deacetylase inhibitor 71 Plasmid DNA 71 Sapacitabine 71 ALTROPANE R 71 MAGE A3 ASCI 71 Hematological Malignancies 71 Complicated Skin 71 targeted antifolate 71 Phase IIb Clinical Trial 71 Ridaforolimus 71 OvaRex R 71 BiTE Antibody 71 Improves Survival 71 Dose Escalation 71 Fungal Infections 71 Milestone Payment 71 Blinatumomab 71 Antithrombin 71 metastatic colorectal 71 Pafuramidine 71 Tezampanel 71 Aliskiren 71 Treating Chronic 71 lexidronam injection 71 HCV polymerase 71 Therapeutic Competitors Companies 70 Deforolimus 70 Phase III Trial 70 siRNA Delivery 70 Phase III Trials 70 Xyfid TM 70 Initiate Phase 70 Hormone Refractory Prostate Cancer 70 Combination Treatment 70 Preclinical Study 70 Liprotamase 70 diarrhea predominant irritable 70 novel therapeutic antibodies 70 HuMax TAC 70 Naive Patients 70 Earns Milestone Payment 70 acetonide FA 70 Monoclonal Antibodies 70 Darinaparsin 70 MOVIPREP R 70 Receives Milestone Payment 70 Metabolic Disorder 70 Epstein Barr Virus EBV 70 Dendritic Cells 70 Antifungal 70 Anticancer Drug 70 Lupus Drug 70 refractory chronic lymphocytic 70 Monoclonal antibody 70 Pivotal Phase III 70 Oral Calcitonin 70 Asthma COPD 70 Phase 2b Study 70 PDX pralatrexate 70 PROSTASCINT R 70 Macrolide 70 cMET 70 Improves Outcomes 70 Onyx Pharmaceuticals Announces 70 Elagolix 70 HCV Protease Inhibitor 70 Assay Kits 70 EVIZON TM 70 SCIB1 70 FDA Approvals 70 Advanced Renal Cell 70 Renal Cell Carcinoma 70 Antibody Drug Conjugate 70 Investigational Compound 70 Rotavirus Vaccine 70 Crit Rev 70 Tigecycline 70 MCSP respectively 70 Neoadjuvant 70 Demonstrates Potential 70 Immunosuppressive 70 Lupus Nephritis 70 Benign Prostatic Hyperplasia 70 Myelodysplastic Syndrome MDS 70 investigational humanized monoclonal antibody 70 Efficacy Trial 70 Neuroprotection 70 Silodosin 70 Molecular Diagnostic 70 Degarelix 70 Combination Therapy 70 Ozarelix 70 Diabetic Foot Ulcer 70 SIX RO ROG 70 Denufosol 70 Potent Antiviral Activity 70 YONDELIS 70 Fludara ® 70 Alfacell proprietary ribonuclease 70 Daclizumab 70 Parathyroid Hormone 70 Chemoprevention 70 Xcytrin R 70 Aptamer 70 evaluating satraplatin 70 fosbretabulin 70 ZEVALIN ® 70 MKC# MT 70 Inflammatory Markers 70 Novel Antibiotic 70 Fast Track Status 70 Nicotine Vaccine 70 Seasonal Influenza Vaccine 70 RNAi therapeutic targeting 70 Pertuzumab 70 Hepatocellular Carcinoma HCC 70 Hepatitis C Virus HCV 70 Onconase 70 trastuzumab DM1 T DM1 70 Panzem R NCD 70 tubulin inhibitor 70 cetuximab Erbitux R 70 StaphVAX R 70 Aplidin R 70 Submits Response 70 Interferon Alpha 70 Maribavir 70 Preclinical Data 70 Phase Ib II 70 Anticancer Agent 70 Phase Ib Clinical Trial 70 accumulate preferentially 70 Teva Provides Update 70 Study Evaluating 70 investigational monoclonal antibody 70 Selective Electrochemical Tumor Ablation 70 docetaxel Taxotere ® 70 Treatment Shows Promise 70 Receives Approvable Letter 70 JAK2 inhibitor 70 IMiDs ® compound 70 NPC 1C 70 Omacetaxine 70 Adult Stem Cell Therapy 70 chronic eosinophilic leukemia 70 evaluating picoplatin 70 gefitinib Iressa 70 Phase III Clinical Trials 70 Non Invasive Treatment 70 targeting CD# 70 PRN FDA Approves 70 Phase III Pivotal 70 Oral Insulin 70 Daptomycin 70 Immune Mediated 70 Progenitor Cell 70 Novolimus 70 Novel Inhibitor 70 acid phosphatase PAP 70 Hypercholesterolemia 70 Fondaparinux 70 BUPHENYL R 70 Amgen Neulasta R 70 Arno Therapeutics 70 candidate deforolimus 69 Smooth Muscle 69 Disease Modifying 69 Autoimmune Disease 69 Confirms Efficacy 69 Tumor Response 69 Lung Cancer Drug 69 monoclonal antibody conjugated 69 FDA APPROVES 69 Subtypes 69 Enlarged Prostate 69 Circulating Tumor Cells 69 Safinamide 69 Novel Mechanism 69 Virosome Biologicals 69 Enzyme Replacement Therapy 69 Plaque Psoriasis 69 Aerosolized 69 Epratuzumab 69 pan HDAC inhibitor 69 Pivotal Trial 69 Crofelemer budesonide foam 69 ® bortezomib 69 Tesmilifene 69 Immune Responses 69 GW# [003] 69 lucinactant 69 Myocardial Perfusion Imaging 69 PNP inhibitor 69 ISTODAX ® 69 FDA Accepts 69 PANVAC VF 69 Mutation Analysis 69 Announces Poster Presentations 69 thetreatment 69 Polymerase Inhibitor 69 C1 Inhibitor 69 epigenetic therapies 69 TNF Tumor Necrosis Factor 69 Patients Receiving 69 TNFerade TM 69 Granted Orphan Drug 69 brivanib 69 CINTREDEKIN BESUDOTOX 69 ATRA IV 69 Tyrosine Kinase Inhibitors 69 Pharmacokinetics PK 69 non nucleoside inhibitor 69 Oral Formulation 69 Dehydrogenase 69 Enzastaurin 69 Inhalation Solution 69 Replacement Therapy 69 Adjuvant Chemotherapy 69 Trastuzumab DM1 69 Hepatitis C Virus 69 Shows Efficacy 69 Potelligent Technology 69 Gets FDA Clearance 69 Panzem NCD 69 NASH Huntington 69 Mg Uk 69 Recombinant Protein 69 Anticonvulsant 69 Polymorphisms 69 Hedgehog Pathway Inhibitor 69 Kidney Transplant Patients 69 Pulmonary Arterial Hypertension 69 Shows Statistically Significant 69 Receive Milestone Payment 69 sorafenib tablets 69 Fibroblast 69 Dalbavancin 69 Therapeutic Targets 69 Cloretazine ® 69 oral picoplatin 69 diagnostic radiopharmaceutical 69 Cytochrome P# 69 Elotuzumab 69 Pivotal Phase 69 EGFR HER2 69 subcutaneous immunoglobulin 69 RhuDex ® 69 DNA Methylation 69 Gastrointestinal Stromal Tumors 69 Fluconazole 69 telomerase therapeutic 69 Psoriasis Drug 69 Alvine Pharmaceuticals 69 oral Janus kinase 69 Eculizumab 69 alemtuzumab MS 69 cardio renal 69 Vaccine Candidate 69 Liposomal 69 ALN PCS 69 vidofludimus 69 TRO# 69 vinorelbine tartrate 69 FUSILEV enhances 69 PKC# 69 Viral Infections 69 generation purine nucleoside 69 Therapeutic Antibodies 69 Bazedoxifene 69 prokinetic agent 69 agonistic human 69 beta 1a 69 SUTENT ® 69 bevacizumab Avastin R 69 Embolic Protection 69 HER2 Positive Breast Cancer 69 Tesetaxel 69 investigational immunotherapy 69 Presents Preclinical 69 Chemotherapeutic Agents 69 Inactivation 69 Test Detects 69 molecular imaging radiopharmaceutical 69 Zemiva TM 69 Glatiramer Acetate 69 Kuvan sapropterin dihydrochloride 69 antisense inhibitors 69 Fc fusion protein 69 Lyophilized 69 Virus Infection 69 Bacteremia 69 Phase 1b Clinical Trial 69 sodium thiosulfate STS 69 Gout Drug 69 Aganocide 69 HuCAL GOLD R 69 Neuroendocrine Tumors 69 Clinical Trial Data 69 Commercialize Novel 69 Regenerative Cells 69 TO AVOID PREGNANCY WHILE 69 Inflammatory Arthritis 69 TKB# 69 KL4 Surfactant 69 Peginterferon alfa 2b 69 MKC# MKC# PP 69 P#X# antagonist 69 vinca alkaloid 69 Unresectable 69 Potent Inhibitor 69 INSPIRE Trial Phase III 69 Maven Semantic 69 OMP #M# 69 Previously Treated 69 non nucleoside HCV 69 novel emulsion formulation 69 RELOVAIR ™ 69 myelodysplastic myeloproliferative diseases 69 Vidaza azacitidine 69 recurrent metastatic ovarian cancer 69 First Patient Dosed 69 Chronic Sinusitis 69 Technosphere ® 69 Begin Clinical Trials 69 Randomized Phase II 69 liposomal formulation 69 Panzem R 69 IgG1 monoclonal antibody 69 Completes Dosing 69 Antisense 69 Posaconazole 69 complement inhibitor eculizumab 69 UPLYSO 69 ABLYNX 69 hypereosinophilic syndrome 69 proprietary polysaccharide 69 Autoimmune Diseases 69 PDE4 inhibitor 69 potent antiproliferative 69 etanercept Enbrel 69 IMiDs ® 69 Xanafide 69 Orally administered 69 Angiogenic 69 Blood Pressure Drug 69 YONDELIS R 69 immuno therapeutic 69 Hematologic 69 IMiDs R 69 Uvidem 69 Pazopanib 69 NABTT 69 Myolimus 69 Hepatocellular 69 ThermoDox ® clinical 69 Thromboembolic 69 Locked Nucleic Acid LNA 69 Bayer HealthCare Onyx Pharmaceuticals 69 RhuDex 69 visit www.genenews.com 69 Glycosylation 69 immunotherapeutic vaccine 69 Mucosal 69 TransVax tm 69 Drug Resistant 69 antiangiogenesis therapies 69 Disease IBD 69 Histone Deacetylase 69 AAG geldanamycin analog 69 Epitopes 69 PF # [002] 69 Drug Prevents 69 antimitotic 69 CTAP# Capsules 69 Regeneron Pharma 69 Squamous 69 Improved Survival 69 Interferon beta 68 molecular diagnostic assay 68 hyaluronidase enzyme 68 Tumor Necrosis Factor 68 Biomarker Study 68 histamine dihydrochloride 68 Phase 1b clinical trials 68 candidate CRLX# 68 Immunomedics Announces 68 Immunosuppressant 68 ThermoDox R 68 Cholesterol Lowering Drug 68 Cytomegalovirus CMV 68 Clolar ® 68 polycythemia vera essential thrombocythemia 68 Archexin 68 Interferon Alfa 68 ERYtech 68 metastatic neuroendocrine tumors 68 INS# [001] 68 Upregulation 68 Interferon beta 1a 68 Chronic Lymphocytic Leukemia 68 Catheter Associated 68 II Clinical Trial 68 protein tyrosine phosphatase 1B 68 acadesine 68 Abstract Accepted 68 Anti VEGF 68 Pandemic Influenza Vaccine 68 including eniluracil ADH 68 Pegylated 68 treat chronic sinusitis 68 simplex virus 68 novel immunotherapeutic 68 Progenitor Cells 68 Mouse Model 68 Varespladib 68 Interferon Gamma 68 Janus kinase 68 benign prostatic hypertrophy BPH 68 Lubiprostone 68 Disease Progression 68 huC# DM4 68 lymphoid malignancies 68 Initiates Dosing 68 immuno modulatory 68 Vitaxin 68 CD# CEA 68 Hematopoietic 68 HCD# [002] 68 Phase 2a Study 68 Doripenem 68 Submits IND 68 iobenguane 68 Analytical Tool 68 Chimigen TM 68 MBRX 68 Cx# [002] 68 Trofex TM 68 Alferon LDO 68 ONCONASE R 68 Quinamed 68 Telbivudine 68 Intravenous Human 68 Milestone Payments 68 Trial Evaluating 68 Adenoviral 68 orally administered inhibitor 68 Combo Therapy 68 Prophylactic Treatment 68 CYP#A# CYP#D# 68 Hormone Receptor Positive 68 Ecallantide 68 Oligonucleotide 68 Radioimmunotherapy 68 ALN TTR 68 Low Dose 68 Pivotal Study 68 PEGylated interferon 68 Placebo Controlled Trial 68 ergot derivatives 68 Cotara ® 68 Novel Anticancer 68 p# inhibitor 68 Bendamustine 68 Thrombin 68 RhuDex TM 68 cathepsin K inhibitor 68 NS5b 68 cellular immunotherapy 68 Nasal Powder 68 Demonstrates Statistically Significant 68 Anti Phospholipid Therapy 68 potent suppressor 68 PSMA ADC 68 NAVISTAR R 68 MGd 68 Exelixis XL# 68 Transfection Reagent 68 Panzem 68 NeoLipid R 68 Humanized Anti 68 FUSILEV ® 68 dasatinib Sprycel ® 68 RNA Interference 68 Decitabine 68 Genes Involved 68 Phase IIb clinical trials 68 Protein Kinase C 68 Tuberculosis Vaccine 68 personalized dendritic 68 Initiates Phase 2b 68 Faropenem 68 Intravitreal 68 Moxifloxacin 68 Anticoagulant 68 selective modulator 68 Human Monoclonal Antibodies 68 TRANSDUR ™ 68 methylnaltrexone bromide 68 JAK Inhibitor 68 Myocet 68 Vitrasert R 68 Homspera TM 68 Soft Tissue Sarcoma 68 immune modulating 68 proteasome inhibitor 68 ZFP Therapeutics 68 sorafenib Nexavar 68 Myelodysplastic Syndromes 68 Anti angiogenic 68 Tumor Microenvironment 68 Treatment Reduces 68 Long Term Efficacy 68 virosome 68 sitaxsentan 68 DermaVir Patch 68 G Protein Coupled 68 Marqibo TM 68 Xeloda ® 68 Invasive Fungal Infections 68 aurora kinase 68 2 methoxyestradiol 68 Sudhir Agrawal D.Phil 68 Cethromycin 68 Receives SFDA Approval 68 Dupuytren Contracture 68 Cytometry 68 Anthrax Toxin 68 Vitro Activity 68 Brentuximab Vedotin SGN 68 Extracellular Matrix 68 Chemokine Receptor 68 CYP#A# substrate 68 Preclinical Development 68 receptor modulators 68 Vion Pharmaceuticals 68 Pegloticase 68 Malignant Melanoma 68 Litx 68 systemic fungal infections 68 Elvitegravir 68 Atypical Hemolytic Uremic Syndrome 68 Effectively Treats 68 Trandolapril 68 antiangiogenic agents 68 Treatment Naïve 68 LEAPS TM 68 Mouse Models 68 Ad5FGF 4 68 intravesical infusion therapy 68 Vaccine Shows Promise 68 Hematological 68 Clinical Trial Enrollment 68 PEG SN# 68 By JENNIFER LEARN 68 G#DT 68 nucleoside analog 68 multicenter Phase II 68 Valopicitabine 68 Mylan Receives Approval 68 vapreotide acetate 68 TLR9 agonist 68 SynCon 68 Romiplostim 68 Protein Synthesis 68 Alinia 68 Rigel R# 68 antineoplastic 68 Hepatocytes 68 Protein Interactions 68 relapsed MM 68 eIF 4E 68 injectable bulking agent 68 novel histone deacetylase 68 Inflammatory Disease 68 Epithelial Cell 68 novel peptide 68 XYOTAX TM 68 selective kinase inhibitor 68 itraconazole Sporanox 68 BRAF mutant 68 Golimumab 68 Rheumatoid Arthritis Patients 68 forodesine 68 delivery polymer matrix 68 Dose Ranging Study 68 Vaccine Adjuvants 68 AVI BioPharma Announces 68 Peripheral Arterial 68 tramiprosate Alzhemed TM 68 Anti Tumor Activity 68 Embolization 68 GTC recombinant human 68 Kuvan R 68 pentostatin 68 sarcoma melanoma 68 INTEGRILIN ® 68 Therapeutic Competitors companiesandmarkets.com adEgemonye 68 Infected Patients 68 adalimumab Humira 68 SinuNase TM 68 COPEGUS R 68 TransVax ™ 68 Randomized Phase 68 Targeted Therapies 68 Percutaneous Tibial Nerve Stimulation 68 Pivotal Clinical Trial 68 HER2 Positive 68 Diagnostic Tests 68 therapeutic monoclonal antibody 67 sunitinib Sutent 67 Gene Silencing 67 TRACON Pharmaceuticals 67 Nitazoxanide 67 Aeolus Pharmaceuticals Announces 67 Talabostat 67 HuLuc# 67 Completes Enrollment 67 Pivotal Phase II 67 Tarceva TM 67 SuperAntibody 67 Trodusquemine MSI 67 Late Breaker 67 Nexavar sorafenib 67 Vascular Disrupting Agent 67 NS#/#A protease 67 BioSante Pharmaceuticals Announces 67 RECOTHROM R 67 relapsed ALL 67 hormone LHRH antagonist 67 IMC #B 67 gastro intestinal inflammation 67 Submits Biologics License Application 67 HGS ETR1 mapatumumab 67 novel peptides 67 Autoimmune Disorders 67 Therapeutic Efficacy 67 advanced metastatic renal 67 Velcade bortezomib 67 pathophysiological effects 67 Brain Metastases 67 Septin9 biomarker 67 pan histone deacetylase 67 galiximab 67 Cloretazine 67 CCR9 antagonist 67 nilotinib Tasigna 67 small molecule thrombopoietin 67 Ampligen ® 67 Nebulized 67 HDL Selective Delipidation 67 novel immunotherapies 67 IAP inhibitors 67 Chronic Heart Failure 67 Novel Compound 67 anti CD3 67 Ovarian Cancers 67 Ercole Biotech 67 Vascular Inflammation 67 Panzem ® 67 Peripheral Blood 67 Pharmacokinetic Study 67 Targeted Therapy 67 HepaLife TM 67 HQK 67 Pooled Analysis 67 microtubule inhibitor 67 immune modulatory 67 Gamunex C 67 Hepatitis B Virus 67 Quantitation 67 TransVax TM 67 Adjuvant Therapy 67 Epilepsy Drug 67 Pandemic Flu Vaccine 67 bladder ovarian 67 human IgG1 monoclonal 67 mda 7 67 Valortim TM 67 THR beta agonist 67 Trofex 67 FS Antihemophilic Factor Recombinant 67 Alferon N 67 successfully commercialize Iluvien 67 Thrombotic 67 Orally Active 67 P#Y# [001] 67 ARIXTRA R 67 Protexia ® 67 HGS ETR2 67 novel immunomodulatory 67 Diabetic Macular Edema 67 BiTE R 67 candidates Azedra 67 Endothelial Cells 67 Well Tolerated 67 DIFICID ™ 67 Identifies Potential 67 R sorafenib tablets 67 Contrast Agent 67 SYN# 67 Cetuximab Erbitux 67 Therapeutic Potential 67 Protease Inhibitors 67 Solid Tumor 67 Significantly Improved 67 CysDisplay R 67 Receptors GPCRs 67 cromolyn sodium 67 Curaxin 67 Files Investigational 67 catheter occlusion 67 Confirmatory Phase 67 Dendritic Cell 67 Paraplatin ® 67 microsphere therapy 67 Friedreich Ataxia FRDA 67 Significantly Improves 67 Develops Novel 67 Medoxomil 67 Optimer Pharma 67 Recurrent Breast Cancer 67 Protexia R 67 oropharyngeal candidiasis OPC 67 adenosine A2A 67 IN PATIENTS WITH 67 Therapeutic Agents 67 Therapeutic Competitors Report 67 Breast Cancer Cells 67 pregabalin Lyrica 67 Metastatic Prostate Cancer 67 Cancer Stem Cells 67 LibiGel ® 67 fluconazole resistant 67 Temsirolimus 67 OMNARIS HFA 67 substantially excreted 67 BioNumerik 67 Antibacterials 67 Metastatic Cancer 67 Anidulafungin 67 Zalypsis 67 Iloperidone 67 Autologous Stem Cell Transplantation 67 personalized cellular immunotherapy 67 Transcription Factor 67 Dasatinib 67 Gleevec resistant 67 Aviptadil 67 samarium Sm 67 ara C 67 Intravenous immunoglobulin 67 include Healive 67 biologic therapeutics 67 Saforis 67 interferon gamma 1b 67 Progressive Multifocal Leukoencephalopathy 67 5 HT2A inverse 67 reslizumab 67 Papillomavirus 67 Blood Glucose Testing 67 SAR# [004] 67 Contrast Agents 67 Radiofrequency Ablation 67 Awarded Qualifying Therapeutic 67 humanised monoclonal antibody 67 LHRH receptor positive 67 carcinoids originate 67 Gleevec imatinib mesylate 67 Pathogenesis 67 vitro pharmacology 67 Cervical Dysplasia 67 Osteoporosis Treatment 67 Commence Phase 67 Randomized Double blind 67 DPX Survivac 67 radiotherapeutic 67 Chronic Hepatitis B 67 DAVANAT 67 mitogen activated ERK kinase 67 Solazed ™ 67 NEUGENE 67 Generx TM 67 bevacizumab Avastin ® 67 familial amyloidotic polyneuropathy FAP 67 midstage clinical 67 STELARA TM 67 Antithrombotic 67 Femring ® 67 Pralatrexate 67 therapeutic monoclonal antibodies 67 PDE# 67 Apaziquone 67 FOLFOX6 chemotherapy regimen 67 corticosteroid dexamethasone 67 docetaxel Taxotere R 67 Survival Benefit 67 Adefovir 67 uricase 67 Kosan dependence 67 oncological indications 67 Talactoferrin 67 indinavir Crixivan 67 Stakeholder Opinions